Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jan;65(1):82–86. doi: 10.1038/bjc.1992.15

Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

H P Henneberry 1, G W Aherne 1
PMCID: PMC1977343  PMID: 1733446

Abstract

In previous pharmacologic studies, the native fluorescent properties of doxorubicin (DOX) have been utilised to visualise tissue and cellular drug distribution. Such distribution studies provide valuable additional information to that obtained by measuring tissue drug concentration alone. An alternative immunocytochemical method of drug localisation using a rabbit immunoadsorbed antiserum to DOX and silver-enhanced gold-labelled second antibodies has been used to achieve visualisation of DOX in normal and malignant tissues from drug-treated animals and patients, and in human tumour cell lines treated in vitro. Non-specific staining in untreated tissues or in controls stained without primary antibody was minimal. Widespread dark brown to black specific immunostaining was observed in the normal tissues of drug-treated animals and in rat sarcoma and in the mouse EMT6 mammary tumour. In human breast tumour biopsy samples obtained at surgery 1 h following a 25 mg intravenous dose of DOX, considerable variation in drug distribution was observed which appeared to be related to drug concentration. Both nuclear and membrane staining was apparent; the latter was especially noticeable in human tumour cells grown in the presence of DOX at concentrations greater than 0.92 microM. Immunolocalisation using silver enhanced gold-labelled reagents provides an additional technique to study cell and organ specific differences in drug uptake and distribution.

Full text

PDF
82

Images in this article

83Figure 1
on p.83
84Figure 2
on p.84
84Figure 3
on p.84
85Figure 4
on p.85

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aghaï E., Tökés Z. A. Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells. Cancer Chemother Pharmacol. 1990;25(4):295–298. doi: 10.1007/BF00684889. [DOI] [PubMed] [Google Scholar]
  2. Bachur N. R., Gee M. V., Friedman R. D. Nuclear catalyzed antibiotic free radical formation. Cancer Res. 1982 Mar;42(3):1078–1081. [PubMed] [Google Scholar]
  3. Cersosimo R. J., Hong W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425–439. doi: 10.1200/JCO.1986.4.3.425. [DOI] [PubMed] [Google Scholar]
  4. Danesi R., Paparelli A., Bernardini N., Del Tacca M. Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1123–1131. doi: 10.1016/0277-5379(88)90118-6. [DOI] [PubMed] [Google Scholar]
  5. Egorin M. J., Clawson R. E., Cohen J. L., Ross L. A., Bachur N. R. Cytofluorescence localization of anthracycline antibiotics. Cancer Res. 1980 Dec;40(12):4669–4676. [PubMed] [Google Scholar]
  6. Faulk W. P., Taylor G. M. An immunocolloid method for the electron microscope. Immunochemistry. 1971 Nov;8(11):1081–1083. doi: 10.1016/0019-2791(71)90496-4. [DOI] [PubMed] [Google Scholar]
  7. Glisson B. S., Ross W. E. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther. 1987;32(2):89–106. doi: 10.1016/0163-7258(87)90054-4. [DOI] [PubMed] [Google Scholar]
  8. Hacker G. W., Springall D. R., Van Noorden S., Bishop A. E., Grimelius L., Polak J. M. The immunogold-silver staining method. A powerful tool in histopathology. Virchows Arch A Pathol Anat Histopathol. 1985;406(4):449–461. doi: 10.1007/BF00710236. [DOI] [PubMed] [Google Scholar]
  9. Henneberry H. P., Aherene G. W., Marks V. Immunocytochemical localisation of VP16-213 in normal and malignant tissues. Cancer Lett. 1987 Oct 30;37(2):225–233. doi: 10.1016/0304-3835(87)90166-2. [DOI] [PubMed] [Google Scholar]
  10. Hindenburg A. A., Gervasoni J. E., Jr, Krishna S., Stewart V. J., Rosado M., Lutzky J., Bhalla K., Baker M. A., Taub R. N. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989 Aug 15;49(16):4607–4614. [PubMed] [Google Scholar]
  11. Holgate C. S., Jackson P., Cowen P. N., Bird C. C. Immunogold-silver staining: new method of immunostaining with enhanced sensitivity. J Histochem Cytochem. 1983 Jul;31(7):938–944. doi: 10.1177/31.7.6189883. [DOI] [PubMed] [Google Scholar]
  12. Kerr D. J., Kaye S. B. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol. 1987;19(1):1–5. doi: 10.1007/BF00296245. [DOI] [PubMed] [Google Scholar]
  13. Lemontt J. F., Azzaria M., Gros P. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res. 1988 Nov 15;48(22):6348–6353. [PubMed] [Google Scholar]
  14. Piall E., Aherne G. W., Marks V. Evaluation of a commercially available radioimmunoassay kit for measurement of doxorubicin in plasma. Clin Chem. 1982 Jan;28(1):119–121. [PubMed] [Google Scholar]
  15. Salmon S. E., Grogan T. M., Miller T., Scheper R., Dalton W. S. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst. 1989 May 3;81(9):696–701. doi: 10.1093/jnci/81.9.696. [DOI] [PubMed] [Google Scholar]
  16. Shinozawa S., Mimaki Y., Araki Y., Oda T. Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr. 1980 Aug 29;196(3):463–469. doi: 10.1016/s0021-9673(00)84748-2. [DOI] [PubMed] [Google Scholar]
  17. Springall D. R., Hacker G. W., Grimelius L., Polak J. M. The potential of the immunogold-silver staining method for paraffin sections. Histochemistry. 1984;81(6):603–608. doi: 10.1007/BF00489542. [DOI] [PubMed] [Google Scholar]
  18. Stallard S., Morrison J. G., George W. D., Kaye S. B. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol. 1990;25(4):286–290. doi: 10.1007/BF00684887. [DOI] [PubMed] [Google Scholar]
  19. Sternberger L. A., Hardy P. H., Jr, Cuculis J. J., Meyer H. G. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem. 1970 May;18(5):315–333. doi: 10.1177/18.5.315. [DOI] [PubMed] [Google Scholar]
  20. Triton T. R., Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science. 1982 Jul 16;217(4556):248–250. doi: 10.1126/science.7089561. [DOI] [PubMed] [Google Scholar]
  21. Weiss L., Mayhew E., Ward P. Drug delivery to tumors. A problem requiring microscopic resolution. Anal Quant Cytol Histol. 1986 Jun;8(2):96–101. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES